P492: Influence of the interval of time between the first and the second anti-TNF in the response to treatment in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P493: Inflammatory sticturing Crohn’s diseases: results of medical treatment
ECCO '19 Copenhagen
2019
P494: Regional survey on satisfaction with healthcare in inflammatory bowel disease patients
ECCO '19 Copenhagen
2019
P495: Spacing the administration interval of anti-TNF agents: a valid strategy for patients with inflammatory bowel disease?
ECCO '19 Copenhagen
2019
P496: Impact of ulcerative colitis on costs, work productivity and quality of life: a prospective study in a single referral centre
ECCO '19 Copenhagen
2019
P497: IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis
ECCO '19 Copenhagen
2019
P498: A nationwide quality improvement program in children with Crohn's disease improves outcomes within 12 months
ECCO '19 Copenhagen
2019
P499: Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2
ECCO '19 Copenhagen
2019
P500: Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
ECCO '19 Copenhagen
2019
P501: High TNF-production of CD14+ cells and short disease duration are independent predictive factors for response to Infliximab treatment
ECCO '19 Copenhagen
2019
P502: Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study
ECCO '19 Copenhagen
2019
P503: Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study
ECCO '19 Copenhagen
2019
P504: How acceptable is a ‘treat to target’ (T2T) approach to IBD patients in clinical remission?
ECCO '19 Copenhagen
2019
P505: Real-world short-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA Registry
ECCO '19 Copenhagen
2019
P506: Steroid treatment for longer than 2 weeks leading to admission predicts higher colectomy rates in children with acute severe ulcerative colitis
ECCO '19 Copenhagen
2019
P507: Efficacy of Infliximab after failure of subcutaneous anti-TNF agents in patients with moderate-to-severe ulcerative colitis
ECCO '19 Copenhagen
2019
P508: Does corticosteroid therapy affect prognosis in inflammatory bowel disease patients hospitalised with Clostridium difficile infection?
ECCO '19 Copenhagen
2019
P509: Long-term outcomes of adalimumab in patients with Crohn’s disease: Can a doubled dose of adalimumab improve outcomes?
ECCO '19 Copenhagen
2019
P510: Infliximab in the very young: it is all about the dosing – a multi-centre study
ECCO '19 Copenhagen
2019